Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1

ACS Infectious Diseases
Terumasa IkedaBrian R McNaughton

Abstract

Drugs that block HIV-1 entry are relatively limited. Enfuvirtide is a 36-residue synthetic peptide that targets gp41 and blocks viral fusion. However, Enfuvirtide-resistant HIV has been reported, and this peptide drug requires daily injection. Previously, we have reported helix-grafted display proteins, consisting of HIV-1 gp41 C-peptide helix grafted onto Pleckstrin Homology domains. Some of these biologics inhibit HIV-1 entry with relatively modest and varied potency (IC50 = 190 nM to >1 μM). Here, we report that gp41 C-peptide helix-grafted Sac7d (Sac7d-Cpep) potently suppresses HIV-1 entry in a live virus assay (IC50 = 1.9-12.4 nM). Yeast display sequence optimization of solvent exposed helix residues led to new biologics with improved expression in E. coli (a common biosimilar expression host), with no appreciable change in entry inhibition. Evolved proteins inhibit the entry of a clinically relevant mutant of HIV-1 that is gp41 C-peptide sensitive and Enfuvirtide resistant. Fusion proteins designed for serum stability also potently suppress HIV-1 entry. Collectively, we report several evolved biologics that are functional against an Enfuvirtide-resistant strain and are designed for serum stability.

References

Mar 7, 2001·Science·M J RootP S Kim
Jul 18, 2002·The Journal of Biological Chemistry·Mark S DennisLisa A Damico
May 21, 2003·Nature Reviews. Drug Discovery·Jason LaBontePeter Kirkpatrick
Aug 13, 2003·Proceedings of the National Academy of Sciences of the United States of America·Samuel K Sia, Peter S Kim
Mar 20, 2004·Nature Reviews. Drug Discovery·Tom MatthewsDani Bolognesi
Jan 20, 2005·Clinical Pharmacokinetics·Indravadan H PatelNeil Buss
Oct 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Brett D WelchMichael S Kay
Oct 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·Yuxian HeQiuyun Dai
Aug 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·W Seth HorneSamuel H Gellman
Jun 18, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ilse VaneyckenNick Devoogdt
Jan 11, 2012·Methods in Enzymology·K Dane WittrupJohn J Rhoden
Jan 15, 2013·Protein Engineering, Design & Selection : PEDS·Ghislaine BéharFrédéric Pecorari
Dec 6, 2014·Chembiochem : a European Journal of Chemical Biology·Susanne N WalkerBrian R McNaughton
Nov 7, 2015·Trends in Microbiology·Oliver F BrandenbergAlexandra Trkola
Nov 27, 2015·Journal of Virology·Yunji W DavenportPamela J Bjorkman
Mar 30, 2016·Current Opinion in Virology·Tomas Cihlar, Marshall Fordyce
Oct 21, 2016·Chembiochem : a European Journal of Chemical Biology·Rachel L TennysonBrian R McNaughton
Aug 16, 2017·Bioorganic & Medicinal Chemistry·Rachel L TennysonBrian R McNaughton
Mar 28, 2018·JAMA : the Journal of the American Medical Association·James RiddellKenneth H Mayer

❮ Previous
Next ❯

Citations

Apr 24, 2019·The Journal of Pharmacology and Experimental Therapeutics·A R Satvik IyengarAbhay H Pande

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

Chembiochem : a European Journal of Chemical Biology
Rachel L TennysonBrian R McNaughton
Current Opinion in Virology
Ben BerkhoutRogier W Sanders
Current Pharmaceutical Design
Dirk EgginkRogier W Sanders
Biochemical Society Transactions
M FrechB A Hemmings
© 2022 Meta ULC. All rights reserved